Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cretostimogene Grenadenorepvec in High-Risk Non-Muscle-Invasive Bladder Cancer
NCT06567743Phase 2Recruiting
- Sponsor
- CG Oncology, Inc.
- Start
- Sep 2024
- Primary completion
- Mar 2027
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 2
01
Overview
A Phase 2 trial of cretostimogene grenadenorepvec in non-muscle-invasive bladder cancer (NMIBC), sponsored by CG Oncology, Inc.. Started Sep 2024; status: recruiting.
02
Drugs
cretostimogene grenadenorepvec
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06567743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06567743.